Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496
This trial is active, not recruiting.
|Treatments||gene expression analysis, microarray analysis, polymorphism analysis, diagnostic laboratory biomarker analysis, immunohistochemistry staining method, immunologic technique|
|Sponsor||Eastern Cooperative Oncology Group|
|Collaborator||National Cancer Institute (NCI)|
|Start date||April 2007|
|Trial size||175 participants|
|Trial identifier||NCT00898963, CDR0000544400, ECOG-E1496T1|
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment.
PURPOSE: This laboratory study is looking at biomarkers in patients with stage III or stage IV follicular lymphoma treated on clinical trial E-1496.
Correlation of gene expression profiles with progression-free survival (PFS)
Prediction of PFS by immunoglobulin Fc-gamma receptor polymorphisms as assessed by immunohistochemistry
Assessment of significance of microenvironment by constructing tissue microarrays and immunostaining with relevant biomarkers
Correlation of relevant biomarkers with clinical features, response, and PFS
Male or female participants at least 18 years old.
DISEASE CHARACTERISTICS: - Diagnosis of follicular lymphoma - Stage III or IV disease - Received cyclophosphamide, vincristine, and prednisone with or without rituximab on clinical trial E-1496 PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - See Disease Characteristics
|Official title||Identification of Biomarkers in Follicular Lymphoma|
|Description||OBJECTIVES: - Correlate gene expression profiles with progression-free survival (PFS) of patients with stage III or IV follicular lymphoma treated with cyclophosphamide, vincristine, and prednisone with or without rituximab on clinical trial E-1496. - Determine if immunoglobulin Fc-gamma receptor polymorphisms are predictive of PFS in these patients. - Assess the significance of the microenvironment by constructing tissue microarrays of follicular lymphoma and immunostaining with relevant biomarkers. - Correlate relevant biomarkers with clinical features, response, and PFS. OUTLINE: This is a multicenter study. Tissue samples are analyzed by gene expression profiling, microarrays to predict gene expression, immunohistochemistry, and immunoglobulin Fc-gamma receptor polymorphism analysis for biological markers. PROJECTED ACCRUAL: A total of 175 samples will be accrued for this study.|
Call for more information